C2 Therapeutics raised $11.6 million in equity funding, according to a recent regulatory filing.
The cash infusion comes just 2 months after the company received FDA clearance for its ablation device to treat a pre-cancerous condition known as Barrett’s esophagus.
People afflicted with Barrett’s esophagus – a condition in which in the tissue lining the throat is replaced by tissue similar to that found in the intestinal lining – are at increased risk for cancer. The condition is often associated with gastric reflex disease, or GERD.
C2’s Coldplay focal cryoballoon ablation system is a “through-the-scope, highly compliant balloon catheter that is simultaneously inflated and cooled by an inert refrigerant delivered from a small disposable handheld unit. The balloon conforms to the shape of the esophageal lumen without exerting excessive tension on the esophageal wall,” according to the company.
Redwood City, Calif.-based C2 did not immediately issue a press release announcing the funding, instead disclosing it via a regulatory filing. In September, the company filed an SEC registration for $2.6 million in debt and warrants.
De Novo Ventures and Synergy list C2 Therapeutics among their portfolio companies.